Watson wins U.S. OK for generic Nicorette mint gum

NEW YORK (Reuters) - U.S. health regulators approved Watson Pharmaceuticals Inc’s generic version of GlaxoSmithKline Plc’s Nicorette mint gum, an over-the-counter product to help smokers quit, Watson said on Wednesday.

Watson plans to make the product, known generically as Nicotine Polacrilex gum, available in early January. Watson won approval for the 2 milligram and 4 milligram strengths.

The market for over-the-counter nicotine gum has annual sales of more than $300 million, according to Watson.

California-based Watson said it has applications pending at the U.S. Food and Drug Administration to market more flavors of nicotine gum as it seeks to enhance its line of smoking cessation products.

(Reporting by Lewis Krauskopf; Editing by Derek Caney)

Source

--------------------------------------------------------------------------------------------
Related Posts:


By Susan Heavey ROCKVILLE, Maryland (Reuters) - The first drug made using genetically engineered animals to near U.S. approval won key support on Friday from an advisory panel that judged it safe and effective despite concerns from groups worried about the genetic tinkering. GTC Biotherapeutics Inc’s experimental anticlotting therapy, called Atryn, is made using a human protein

Full Post: U.S. advisers back 1st drug from DNA-altered animals
--------------------------------------------------------------------------------------------

Wellbutrin is an atypical antidepressant. It is a medication for those who want to give up smoking. Wellbutrin does not contain nicotine and is a very effective smoking cessation treatment. The effect of Wellbutrin consists in reduction of smoking cessation symptoms. Wellbutrin is an ideal medicine which facilitates the process of smoking cessation. This medicine

Full Post: Wellbutrin - an easy way to give up smoking
--------------------------------------------------------------------------------------------

BOSTON (Reuters) - Allergan Inc, maker of Botox, said on Friday that the U.S. Food and Drug Administration has approved its eyelash-thickening drug Latisse. Latisse is designed to treat a condition known as hypotrichosis of the eyelashes, in which a person has does not have enough eyelashes. The active ingredient in Latisse is bimatroprost, the same ingredient

Full Post: FDA approves Allergan’s drug for longer eyelashes
--------------------------------------------------------------------------------------------

BRUSSELS (Reuters) - Belgian health products distributor Omega Pharma will launch a chip it claims can counter potentially damaging radiation from mobile phones and has high hopes for its sales. The company, which sells non-prescription products such as wart treatments, pregnancy tests and sun tan lotions to pharmacists, unveiled the E-waves phone chip on Tuesday, a

Full Post: Mobile phone chip to counter radiation unveiled
--------------------------------------------------------------------------------------------

WASHINGTON (Reuters) - U.S. health regulatory staff have questioned whether there are enough data to show that Female Health Co’s latest condom for women prevents pregnancy and sexually transmitted diseases, according to documents released on Tuesday. The Chicago-based company is seeking Food and Drug Administration approval to sell its new version, called the FC2 Female Condom,

Full Post: FDA staff debate data for new female condom

Site Navigation

Most Read

Search